Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Purchased by Versor Investments LP

Versor Investments LP grew its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 191.3% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 40,200 shares of the company’s stock after acquiring an additional 26,400 shares during the quarter. Versor Investments LP’s holdings in Amneal Pharmaceuticals were worth $334,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in the stock. Rothschild Investment LLC acquired a new position in Amneal Pharmaceuticals in the 2nd quarter valued at about $26,000. DekaBank Deutsche Girozentrale purchased a new stake in shares of Amneal Pharmaceuticals during the second quarter worth about $42,000. Atlanta Consulting Group Advisors LLC acquired a new position in shares of Amneal Pharmaceuticals in the first quarter valued at approximately $61,000. nVerses Capital LLC purchased a new position in shares of Amneal Pharmaceuticals during the second quarter valued at approximately $62,000. Finally, Bayesian Capital Management LP acquired a new stake in Amneal Pharmaceuticals during the first quarter worth approximately $65,000. 31.82% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have weighed in on AMRX shares. Barclays boosted their price target on Amneal Pharmaceuticals from $8.00 to $10.00 and gave the company an “overweight” rating in a report on Tuesday, August 13th. Truist Financial increased their target price on Amneal Pharmaceuticals from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Wednesday, October 2nd. StockNews.com upgraded Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Monday, November 11th. JPMorgan Chase & Co. upgraded shares of Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 price objective on the stock in a report on Friday, September 6th. Finally, Piper Sandler boosted their target price on shares of Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an “overweight” rating in a report on Monday, November 11th. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Amneal Pharmaceuticals presently has an average rating of “Buy” and an average price target of $10.00.

Amneal Pharmaceuticals Stock Performance

Shares of NASDAQ:AMRX opened at $8.47 on Friday. Amneal Pharmaceuticals, Inc. has a 1 year low of $4.16 and a 1 year high of $9.48. The stock has a 50-day simple moving average of $8.58 and a 200-day simple moving average of $7.63. The stock has a market capitalization of $2.62 billion, a P/E ratio of -12.59 and a beta of 1.17.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.